Cesare Gridelli
Azienda Ospedaliera S.Giuseppe Moscati · 71 works · 3,772 citations · h-index 21
Top works
- Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer
- Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial
- PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
- Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project
- Gemcitabine as Second-Line Treatment for Advanced Non–Small-Cell Lung Cancer: A Phase II Trial
- Treatment of Advanced Non–Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
- A three-week schedule of gemcitabine–cisplatin in advanced non-small-cell lung cancer with two different cisplatin dose levels: A phase II randomized trial
- Vinorelbine is Well Tolerated and Active in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. A Two-stage Phase II Study
- Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients
- Quality of life in lung cancer patients
- PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).
- Pemetrexed in the treatment of advanced non-squamous lung cancer
- Treatment of advanced non-small cell lung cancer
- Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer
- Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone in patients with advanced non-small cell lung cancer and a performance status of 2: The CAPPA-2 study
- Gemcitabine as second-line treatment for relapsing or refractory advanced non-small cell lung cancer: a phase II trial.
- Combined targeted therapies in non-small cell lung cancer: a winner strategy?
- Thoracic radiotherapy and daily vinorelbine as radiosensitizer in locally advanced non small cell lung cancer: a phase I study
- Gefitinib (ZD1839) combined with gemcitabine or vinorelbine as single-agent in elderly patients with advanced non-small cell lung cancer (NSCLC)
- Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors